Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
28 juin 2022 08h05 HE
|
Akoya Biosciences, Inc.
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted...
Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual Meeting
01 juin 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, will present for the first time, data generated using its proprietary RNA...
Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
05 mai 2022 16h05 HE
|
Akoya Biosciences, Inc.
Q1 2022 revenue $16.9 million, 38% growth over prior year periodRaising FY 2022 revenue guidance range to $70-73 million MARLBOROUGH, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences,...
Akoya to Participate at Three Upcoming Investor Conferences
03 mai 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming...
Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer
19 avr. 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company’s...
Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022
14 avr. 2022 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022
06 avr. 2022 08h05 HE
|
Akoya Biosciences, Inc.
Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the tumor microenvironmentThe Company will also showcase its novel protein chemistry to accelerate...
Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook
14 mars 2022 16h05 HE
|
Akoya Biosciences, Inc.
Q4 2021 revenue $16.2 million and FY 2021 revenue $54.9 millionFY 2022 revenue guidance $69 - 71 million MARLBOROUGH, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq:...
Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022
22 févr. 2022 08h00 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
03 févr. 2022 08h00 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the...